NIGP 26956: Gastrointestinal Drugs

NIGP 26956 Gastrointestinal Drugs, an Item code, does not align with the actual state and local procurement activity appearing under this classification. Recent opportunities posted under this code involve offender drug testing services, water treatment chemicals (sodium hypochlorite and sulfuric acid), and pharmaceutical benefit management strategy exploration—none of which are gastrointestinal pharmaceuticals. State and local governments are using this code to solicit specimen collection and drug-testing operations, industrial and municipal chemicals for water treatment, and vendor capacity assessments for direct-to-manufacturer prescription programs. The issuing bodies span county criminal-justice departments (Collin County Community Supervision and Corrections Department in Texas), county public-works and utility agencies (County of Orange, California), and state health commissions (Texas Health and Human Services Commission). The activity suggests either miscoding in the underlying procurement system or repurposing of the gastrointestinal-drugs taxonomy to accommodate broader pharmacy and chemical procurement that state and local agencies are consolidating under existing NIGP structures.

Collin County, Texas issued RFP 2026-327 on July 9, 2026 for offender specimen collection and drug testing services, with proposals due July 23, 2026; the estimated contract value is $600,000 over two years commencing September 1, 2026, with three optional one-year renewals. The County of Orange, California issued IFB 080-3008401-RE for sodium hypochlorite and sulfuric acid supply to support water treatment operations, with bids due March 27, 2026; the contract term runs five years from September 30, 2026, with five-percent preference deductions for certified Orange County Local Small Businesses and eight-percent deductions for vendors certified as both OCLSB and Disabled Veteran Business Enterprises. Texas Health and Human Services Commission issued RFI HHS0017013 on March 27, 2026 (response deadline April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program—an exploratory phase preceding formal RFP issuance. Activity concentrates in California and Texas, with no recent opportunities in other states represented in the current data.